Is Wegovy bad for your liver — or could it actually help?

Does semaglutide damage the liver?

The short answer is no, not in people with otherwise healthy or mildly affected livers. GLP-1 medicines like semaglutide work partly by reducing overall calorie intake, which in turn lowers the accumulation of fat in the liver. Multiple trials in people with metabolic fatty liver disease have shown meaningful reductions in liver fat content and improvements in inflammation markers over treatment periods ranging from 24 to 72 weeks. The NHS patient information for semaglutide does not list liver damage among its recognised adverse effects.

The most significant regulatory signal in this area came on 3 July 2026, when the MHRA granted a conditional approval for Wegovy to treat MASH in adults with moderate-to-advanced liver fibrosis, making it the first GLP-1 medicine to receive a UK authorisation specifically for liver disease. You can read the MHRA's announcement on GOV.UK for the precise scope of that approval. This is an important context: the same medicine people ask about fearing liver harm has now been licensed to treat a serious liver condition. That does not mean it is risk-free, or that everyone with liver disease is automatically suitable, clinical assessment still matters enormously here.

For people whose weight-related fatty liver has not yet progressed to MASH, weight loss through any route (including GLP-1 treatment) is widely recognised as beneficial for liver health. The Wegovy overview on our site covers the broader picture of how semaglutide supports weight management in adults with obesity.

Are there liver-related risks anyone starting Wegovy should know about?

A few deserve honest attention. Gallbladder problems (including gallstones and inflammation of the gallbladder) are a recognised side effect of weight loss and appear in the known risk profile of GLP-1 medicines. Rapid weight loss (from any cause) increases cholesterol saturation in bile and can trigger stone formation. Semaglutide also slows gastric emptying, which may affect bile flow. This is not unique to Wegovy, but it is real. Severe or persistent pain in your upper right abdomen (particularly after eating fatty food) warrants prompt medical review rather than waiting for your next prescription check.

People with severe pre-existing liver impairment were not well-represented in the main semaglutide weight-management trials, so there is less direct evidence for that group. If you have cirrhosis or another significant liver condition, a prescriber and likely a hepatology specialist should be part of the decision. This is not a reason to panic; it is a reason to be thorough. The fuller clinical discussion about semaglutide and liver function explores this in more detail.

Pancreatitis (which affects an organ close to the liver and can sometimes be confused with liver pain) was the subject of an MHRA Drug Safety Update in January 2026. Severe, persistent stomach pain that radiates to the back, with or without vomiting, should be treated as a medical emergency. Report any suspected side effects via the MHRA's Yellow Card scheme.

What if you already have a liver condition, can you still use Wegovy?

Possibly, but it depends entirely on the nature and severity of the condition. For people with non-alcoholic fatty liver disease (NAFLD) or its more serious form MASH, semaglutide is now one of the most evidence-backed interventions available. For people with well-compensated mild-to-moderate liver disease, the evidence is broadly reassuring. For severe hepatic impairment, the picture is more cautious and the clinical data thinner.

If you are managing a liver condition alongside obesity and wondering whether Wegovy might help (or whether it could complicate things) that conversation genuinely belongs with your GP or hepatologist first, and then with the prescriber carrying out your weight-management assessment. Our clinical team at nume reviews every consultation in detail, and liver-related health history is part of what they consider. Transfer patients or those with complex medical backgrounds are welcome to contact us to discuss whether a private consultation is appropriate for their situation.

It is also worth knowing that Wegovy's impact on the cardiovascular system is a separate topic that matters in people with liver-related metabolic conditions, and if you want to understand whether Wegovy is good for your heart, that page covers the cardiovascular safety evidence in detail. And if you are exploring treatment options more broadly, the free consultation page is the clearest starting point.

What should you do if you are concerned about your liver while taking Wegovy?

First: do not stop treatment without speaking to your prescriber. Stopping a GLP-1 medicine abruptly does not protect your liver and may result in rapid weight regain, which itself carries metabolic consequences. If you have a concern, raise it promptly, with the prescriber who issued your prescription, your GP, or, if symptoms are acute, by calling NHS 111 or attending A&E.

Signs that need same-day or emergency attention: yellowing of the skin or eyes (jaundice), very dark urine, severe right-sided abdominal pain, or anything that feels sudden and severe. These are not common on Wegovy, but they are not things to wait on.

For ongoing questions about how semaglutide interacts with other aspects of your health, our frequently asked questions page covers a range of common concerns, and our prescribers are available seven days a week for aftercare queries. If you are still deciding whether Wegovy is right for you (particularly if you have a liver condition in the background) reading about how Wegovy can affect liver function may give you a fuller picture before your consultation. For anyone curious about the broader evidence on semaglutide's metabolic effects, the dedicated semaglutide and liver health page goes deeper into the trial data. A good place to start, whenever you are ready, is the weight-loss treatment overview.